By visiting our website or using services provided by Sai Life Sciences, you are accepting the practices described in the Privacy Policy.

We also use cookies on our websites. Cookies allow us to give you the best browsing experience and help us to understand how you use our site. You can disable cookies but parts of our website may not work. By continuing to use this website, you agree that we may store and access cookies on your device.

By clicking “I Accept”, you confirm that you are above the age of 16, that you have read and understood the Cookies Usage and the Privacy Policy, and that you agree to the collection, use and processing of your Personal Information by Sai Life in accordance with said policies.

I accept

Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2024.10.28

Advanced manufacturing facility at Sai Life Sciences, showcasing state-of-the-art equipment and quality control, featured in a blog post about receiving Establishment Inspection Reports (EIRs) from the USFDA.

Sai Life Sciences receives EIRs from USFDA for India R&D & Manufacturing facilities

Sai Life Sciences, the fastest-growing Indian Contract Research, Development and Manufacturing Organization (CRDMO)[1], announced that it has received Establishment Inspection Reports (EIR) from the US Food and Drug Administration (USFDA) for its R&D (Unit II, Hyderabad), and Manufacturing (Unit IV, Bidar) sites in India.

The General Good Manufacturing Practices (GMP) audit was conducted at the integrated R&D campus (Unit II) in April 2024, while the pre-approval inspection (PAI) & General GMP audit was conducted at the Manufacturing facility (Unit IV) in Bidar in June 2024.

Making the announcement, Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences, said, “These audit outcomes reflect Sai Life Sciences’ commitment to maintaining the highest standards of quality and compliance across its R&D and manufacturing facilities. It demonstrates the company’s robust quality systems and its readiness to support the supply of high-quality pharmaceutical products to global markets."

[1] Among listed Indian peers in terms of revenue CAGR as well as EBITDA CAGR over FY22-24.

Share article

More News

2025.02.07

Sai Life Sciences headquarters, symbolizing innovation and growth, featured in a blog post about the company's strong quarterly report performance.

Sai Life Sciences Limited reports robust quarterly results

Revenue grows by 15%; Net Profit up 36% year-on-year Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE), an innovator focused, Contract Research and Development Organization (CRDMO) today announced its financial results for the third quarter and nine months ended December 31, 2024. Financial Performance: Particulars (₹ crores) Q3FY25 Q3FY24 YoY% 9MFY25 9MFY24 YoY% Revenue […]
Read more

2025.01.01

Before and after comparison of the historic Manchirevula stepwell restoration by Sai Life Sciences, showcasing transformation from a neglected site to a well-maintained water body near a temple.

Sai Life Sciences completes restoration of historic Manchirevula stepwell

As part of its Corporate Social Responsibility (CSR) initiative, Sai Life Sciences, in collaboration with the Society for Advancement of Human Endeavours (SAHE), completed the restoration of the historic stepwell dating back to the 17th century at the Sri Venugopala Swamy temple premises, located in Manchirevula, Hyderabad. The Manchirevula Stepwell Restoration Project was undertaken with […]
Read more

2024.10.07

Sai Life Sciences' eco-friendly campus with green landscaping and modern architecture at sunset, featured in a blog post about the company's 2024 Sustainability Report

Sai Life Sciences releases Sustainability Report 2024

Sai Life Sciences, the fastest-growing Indian Contract Research, Development and Manufacturing Organization (CRDMO)[1], published its Sustainability Report for 2023-2024. Aligned with the Global Reporting Initiative (GRI) Universal Standards 2021 framework, this fifth edition of the Sustainability Report is based on the theme, ‘Synergising Sustainability, Performance and Growth.’ The full report can be read here. Making […]
Read more

2024.08.09

Sai Life Sciences scientist accessing a -40.2°C ultra-low temperature storage unit as part of the advanced Compound Management process, enhanced by the in-house CORAL software application.

Sai Life Sciences elevates Compound Management process with in-house software application, CORAL

Compound management is a vital function in pharmaceutical research. A streamlined environment can bring significant value to the process in the form of productivity and efficiency. Recognizing the importance of this function, we have made our Compound Management suite for Discovery services smarter with the introduction of an in-house software application, Compound Organization and Registration […]
Read more

2024.07.29

A smiling trainee in a Sai Life Sciences uniform during an induction event, representing the company's commitment to nurturing young talent across its campuses in India.

Sai Life Sciences inducts 96 trainees across campuses in India

“I just got my first pair of safety shoes and I’m thrilled! Exploring the facility for the first time is such a joy!” – Spurthi R, Trainee, Medicinal Chemistry, Shamirpet. Ushering in a season of new beginnings, we welcomed 96 trainees across our campuses in India. These young individuals have been selected from eight colleges […]
Read more